DeCure's autonomous Nephrology AI scientist is researching a drug-repurposing hypothesis for urethritis — screening already-approved drugs against its 26-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleUrethritis maps to a 26-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for urethritis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
matrix metallopeptidase 7 (MMP7) — MMP7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 2Y6D · 1.6 Å · ligand N-[(2S)-1-[4-(5-BROMOPYRIDIN-2-YL)PIPERAZIN-1-YL]SULFONYL-5-PYRIMIDIN-2-YL-PENTAN-2-YL]-N-HYDROXY-METHANAMIDE (TQJ). Experimental structure, not a prediction.
What the evidence adds up to
The first abstract is a general review of urethritis assessment and management in UK clinics; it contains no original data on any drug or treatment outcome.
A 2015 retrospective study of 1194 men attending an STI clinic in Providence, Rhode Island found that 125 (10%) reported symptoms of urethritis. Among those symptomatic men, 22% had chlamydia, 10% had gonorrhoea, 2% had both, and 66% had neither (non-gonococcal, non-chlamydial urethritis). Men who had sex with men (MSM) were more likely than men who had sex only with women (MSF) to test positive for gonorrhoea (26% versus 6%, p<0.01), but there was no difference between groups in chlamydia or non-gonococcal, non-chlamydial urethritis. MSF were more likely than MSM to present with symptoms (12% versus 8%, p=0.03). The average number of anal/vaginal sex partners in the last 12 months did not differ between groups (3.5 for MSF versus 3.9 for MSM, p=0.60), nor did the number of partners with condomless sex (1.7 versus 1.5, p=0.82). The authors concluded that the aetiology of symptomatic urethritis differs by sexual preference and that a large proportion of cases remain unexplained by standard STI testing.
A 1998 chapter states that urethritis is a clinical syndrome characterised by urethral discharge and dysuria, that the pathognomonic laboratory finding is increased polymorphonuclear leukocytes on a urethral smear, and that the condition is almost always sexually acquired, though coliform bacteria or non-infectious causes are occasionally responsible. No drug, treatment, or outcome data are reported.
No abstract in this set reports a drug trial, a repurposing attempt, or any treatment outcome. What is missing is any randomised controlled trial testing a specific drug for urethritis, any data on patient stratification beyond sexual behaviour, and any funding for a repurposing study in this condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
InnovAiT Education and inspiration for general practice · 2021 · 0 citations
Urethritis in men
AbstractUrethritis is simply defined as inflammation of the urethra. In the majority of cases, urethritis is caused by a sexually transmitted infection. Urethritis is the most common condition diagnosed and treated among men attending genito-urinary medicine (GUM) clinics in the UK. This article aims to outline the assessment and management of urethritis in both primary care and GUM clinics.
AbstractAbstract Urethritis is a clinical syndrome generally characterized by urethral discharge and dysuria. It may be complicated by epididymitis and orchitis, which are also discussed in this chapter. The pathognomonic laboratory finding in urethritis is an increased number of polymorphonuclear leukocytes (PMN) on the gram stain of a urethral smear. Some patients have increased PMNs on urethral smear but lack symptoms of infection, so some cases are considered asymptomatic. Urethritis is almost always sexually acquired, but occasionally it derives from coliform bacteria or noninfectious causes.
The efficiency of combination therapy of non-gonococcal urethritis in men
AbstractAIM: To carry out a comparative assessment of the efficiency of combination therapy for non-gonococcal urethritis (NGU) in men. MATERIALS AND METHODS: a total of 124 patients with NGU and laboratory-confirmed urogenital infection were included in the study. The diagnostic methods included microscopy of urethral smear, real-time polymerase chain reaction (PCR) for the detection of uropathogens and laser Doppler flowmetry for evaluating the urethral microcirculation. All patients were randomized into three groups matched for age, clinical manifestations, and disease duration. Patients of the group 1 received targeted antibiotic therapy. In the group 2, local peloid therapy was added, while patients in group 3 additionally received vibromagnetotherapy. The control group consisted of 22 patients aged 18 to 55 years. The study included 2 visits, at the baseline and 4 weeks after the end of treatment. RESULTS: After the treatment, the frequency of microbiological cure was 89%. In the group 3, more pronounced improvement in main symptoms of NGU was observed. The analysis of microcirculation after treatment in the groups 2 and 3 showed a significant increase in perfusion and modulation of urethral blood flow and a decrease in venous congestion after combined therapy. CONCLUSION: The combined treatment, including antibiotic, peloid therapy, and vibromagnetotherapy, promotes more pronounced clinical improvement, restoration of urethral microcirculation and relief of inflammatory process in patients with NGU and can be recommended for routine clinical practice.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
